Hair Follicle Melanocytes Initiate Autoimmunity in Alopecia Areata: a Trigger Point

Clinical Reviews in Allergy & Immunology, Journal Year: 2022, Volume and Issue: 63(3), P. 417 - 430

Published: Sept. 19, 2022

Language: Английский

---

Treatment update for vitiligo based on autoimmune inhibition and melanocyte protection

Expert Opinion on Therapeutic Targets, Journal Year: 2023, Volume and Issue: 27(3), P. 189 - 206

Published: March 4, 2023

Introduction The treatment of vitiligo remains challenging due to the complexity its pathogenesis, influenced by genetic factors, oxidative stress and abnormal cell adhesion that collectively impact melanocyte survival trigger immune system attacks, resulting in death. Melanocytes are believed exhibit susceptibility defects cellular mechanisms, such as autophagy, reduce their ability resist stress, leading increased expression pro-inflammatory protein HSP70. low molecules, DDR1 E-cadherin, accelerates damage antigen exposure. Consequently, autoimmune attacks centered on IFN-γ-CXCR9/10-CXCR3-CD8+ T cells initiated, causing vitiligo.

Language: Английский

---

Effectiveness, Tolerability and Safety of Topical Clobetasol with Oral Hydroxychloroquine versus Topical Clobetasol with NBUVB Phototherapy in Unstable Vitiligo: Investigator Blind, Randomized Controlled Trial

Indian Journal of Dermatology, Journal Year: 2025, Volume and Issue: 70(2), P. 115 - 115

Published: Feb. 27, 2025

Vitiligo is an acquired multifactorial depigmentation disorder with dreadful social stigma without any gold standard treatment option. Treatment of unstable vitiligo is, furthermore limited. Hydroxychloroquine has shown promise in a few case reports. The effectiveness, tolerability and safety narrow-band ultraviolet B (NBUVB)-plus topical clobetasol (group A) versus oral hydroxychloroquine-plus (0.05%) B) were evaluated. Single-centre, investigator-blind, randomised, active-controlled, parallel-group phase IV trial (CTRI/2019/07/020345) was conducted on either sex. Patients randomised into two groups (1:1 allocation ratio), concealment ensured by the sequentially numbered, sealed, opaque envelope technique. assessing physician unaware regarding allocation. Outcome measures area scoring index (VASI), disease activity score (VIDA) dermatology life quality (DLQI). economic burden therapy calculated terms travel costs loss time for availing therapy. Routine haematological biochemical tests treatment-emergent adverse events monitored safety. sample size 82 (5% alpha-error, 80% power, 61.1% 30% percentage improvement study groups, 10% drop-out). Intention-to-treat analysis showed significant VASI (Friedman's variance, P < 0.01) group A (1048.00 ± 1450.10 reduced to 933.43 1387.79) (415.00 458.47 283.85 386.61) at end-of-treatment visit (24th week). Improvement noted from 12 weeks onwards eight (post-hoc Dunn's test, 0.001). Within comparison significantly more than (P 0.05, covariance test baseline as covariate). similar result obtained VIDA. DLQI improved only B. monthly cost less (Mann-Whitney's 0.5) A. No group. Both NBUVB hydroxychloroquine combined are safe effective agents vitiligo, though faster hydroxychloroquine. With hydroxychloroquine, there no infrastructural requirement, working hours opposed NBUVB, which needs set-up.

Language: Английский

---

Vitamin D and systemic lupus erythematosus: Causality and association with disease activity and therapeutics

Biochemical Pharmacology, Journal Year: 2024, Volume and Issue: 227, P. 116417 - 116417

Published: July 10, 2024

Language: Английский

---